[시장보고서]세계의 자가면역질환 진단 시장(-2031년) : 제품별, 검사 유형별, 질환 유형별, 최종 사용자별, 지역별 예측

세계의 자가면역질환 진단 시장(-2031년) : 제품별, 검사 유형별, 질환 유형별, 최종 사용자별, 지역별 예측

Autoimmunity Diagnostics Market by Product (Consumables, Instruments), Test Type (Routine, Autoantibody, Inflammatory, Urinalysis Tests), Disease (RA, SLE, MS, IBD), End User (Clinical Laboratories, Hospitals & Clinics) - Global Forecast to 2031

상품코드 : 1788519 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2025년 08월

페이지 정보 : 영문 299 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,184,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,651,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,828,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,514,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

자가면역질환 진단 시장 규모는 예측 기간 동안 8.3%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 2025년 55억 7,000만 달러에서 2031년에는 89억 8,000만 달러에 이를 것으로 예측됩니다.

조사 범위
조사 대상연도	2024-2031년
기준연도	2024년
예측 기간	2025년-2031년
조사 단위	금액(10억 달러)
부문	제품별, 검사 유형별, 질환 유형별, 최종 사용자별 : 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

이 성장의 원동력은 자가면역질환의 유병률 상승, 조기 진단에 대한 의식 증가, 다중 면역 측정법 및 바이오마커 기반 검사 등의 기술적 진보에 의해 발생합니다. 또한, 자동화 플랫폼의 채용 확대와 정부의 지원책이 검사량 증가나 진단 정밀도의 향상에 기여하고 있습니다.

질병 유형별로 세계의 자가면역질환 진단 시장은 전신성 자가면역질환과 장기특이적 자가면역질환으로 구분됩니다. 전신성 자가면역질환 부문은 2024년 최대 시장 점유율을 차지했습니다. 이 지역의 높은 점유율은 류마티스 관절염, 전신성 홍반성 루푸스, 다발성 경화증과 같은 질병이 널리 확산되어 있기 때문입니다. 이러한 질병은 일반적으로 여러 장기와 시스템에 영향을 미치므로 빈번하고 종합적인 진단 평가가 필요합니다. 진단의 복잡성, 고급 면역학적 검사에 대한 의존성, 지속적인 질병 모니터링의 필요성은 이 부문에서 진단 솔루션 수요를 증가시키고 있습니다.

최종 사용자별로 보면 자가면역질환 진단 시장은 임상검사실, 병원 및 진료소, 기타 최종 사용자로 구분됩니다. 이 중 임상검사실 부문은 전문적인 지식, 고급 진단 기술 및 높은 처리량 능력으로 최대 시장 점유율을 차지했습니다. ELISA, 화학발광, 면역형광과 같은 자동화된 플랫폼을 갖춘 이러한 실험실은 복잡한 검사를 높은 정확도와 효율성으로 수행할 수 있습니다. 또한 중앙 집중식 검사 허브 역할을 하면서 검사 1건당 비용을 줄여 대량의 샘플을 처리할 수 있습니다.

자가면역질환 진단 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 아시아태평양 시장은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예측됩니다. 이 지역의 높은 성장률은 주로 자가면역질환의 유병률 증가, 건강 관리 지출 증가, 고도 진단 기술 채택 확대, 신흥국 내 전반적인 질병의 조기 발견에 대한 의식 증가에 의해 발생합니다. 또한 건강 관리 인프라 개선 및 정부 지원 조치도 아시아태평양의 시장 확대에 기여하고 있습니다.

본 보고서에서는 세계의 자가면역질환 진단 시장에 대해 조사했으며, 제품별, 검사 유형별, 질환 유형별, 최종 사용자별, 지역별 동향, 시장 진출기업 프로파일 등을 정리했습니다.

소개
시장 역학
가격 분석
특허 분석
밸류체인 분석
공급망 분석
무역 분석
생태계 분석
Porter's Five Forces 분석
주요 이해 관계자와 구매 기준
기술 분석
2025-2026년의 주요 회의와 이벤트
고객의 비즈니스에 영향을 미치는 동향/혼란
투자 및 자금조달 시나리오
사례 연구 분석
AI/생성형 AI가 자가면역질환 진단 시장에 미치는 영향
트럼프 관세가 자가면역질환 진단 시장에 미치는 영향

제6장 자가면역질환 진단 시장(제품별)

소개
소모품
기기

제7장 자가면역질환 진단 시장(검사 유형별)

소개
자가항체와 면역학적 검사
정기적인 임상 검사
염증 검사
소변 검사
기타

제8장 자가면역질환 진단 시장(질환 유형별)

소개
전신성 자가면역질환
장기특이적 자가면역질환

제9장 자가면역질환 진단 시장(최종 사용자별)

소개
임상검사실
병원 및 클리닉
기타

제10장 자가면역질환 진단 시장(지역별)

소개
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카

제11장 경쟁 구도

소개
주요 진입기업의 전략/강점
수익 분석(2022-2024년)
시장 점유율 분석(2024년)
기업평가 매트릭스 : 주요 진입기업(2024년)
기업평가 매트릭스 : 스타트업/중소기업(2024년)
기업평가와 재무 측정항목
브랜드/제품 비교
경쟁 시나리오

제12장 기업 프로파일

주요 진출기업
- F. HOFFMANN-LA ROCHE LTD.
- ABBOTT LABORATORIES
- REVVITY, INC.
- THERMO FISHER SCIENTIFIC INC.
- SIEMENS HEALTHINEERS AG
- BIO-RAD LABORATORIES, INC.
- GRIFOLS SA
- WERFEN SA
- EXAGEN INC.
- TRINITY BIOTECH PLC
- TECAN GROUP LTD.
- DANAHER CORPORATION
- BIOSYNEX SA
- QUIDELORTHO CORPORATION
- BIOMERIEUX SA
- DIASORIN SPA
기타 기업
- BECTON, DICKINSON AND COMPANY
- SD BIOSENSOR, INC.
- CAMBRIDGE LIFE SCIENCES LTD
- A. MENARINI DIAGNOSTICS SRL
- SEBIA
- KRONUS
- ERBA GROUP
- AESKU.GROUP GMBH
- MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
- EPITOPE DIAGNOSTICS INC.

제13장 부록

CSM

영문 목차

영문목차

The autoimmune disease diagnosis market is projected to reach USD 8.98 billion by 2031 from USD 5.57 billion in 2025, at a CAGR of 8.3% during the forecast period.

Scope of the Report
Years Considered for the Study	2024-2031
Base Year	2024
Forecast Period	2025-2031
Units Considered	Value (USD billion)
Segments	Product, Test Type, Disease Type, and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

This growth is driven by the rising prevalence of autoimmune disorders, increasing awareness of early diagnosis, and technological advancements such as multiplex immunoassays and biomarker-based tests. Additionally, the growing adoption of automated platforms and supportive government initiatives contribute to increased testing volumes and improved diagnostic accuracy.

By disease type, the systemic autoimmune diseases segment accounted for the largest market share in 2024.

Based on disease type, the global autoimmune disease diagnosis market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. The systemic autoimmune diseases segment accounted for the largest market share in 2024. The large share of this region is attributed to the widespread prevalence of conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. These diseases typically affect multiple organs and systems, necessitating frequent and comprehensive diagnostic evaluations. The complexity of diagnosis, reliance on advanced immunological tests, and the need for continuous disease monitoring drive higher demand for diagnostic solutions in this segment.

By end user, the clinical laboratories segment accounted for the largest market share during the forecast period.

Based on end users, the autoimmune disease diagnosis market is segmented into clinical laboratories, hospitals & clinics, and other end users. Among these, the clinical laboratories segment accounted for the largest market share owing to specialized expertise, advanced diagnostic technologies, and high-throughput capabilities. Equipped with automated platforms such as ELISA, chemiluminescence, and immunofluorescence, these laboratories can perform complex tests with high accuracy and efficiency. Their role as centralized testing hubs allows them to process large sample volumes at reduced per-test costs.

Asia Pacific: The fastest-growing region in the autoimmune disease diagnosis market during the forecast period.

The autoimmune disease diagnosis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the region is primarily driven by the rising prevalence of autoimmune diseases, increasing healthcare expenditure, the growing adoption of advanced diagnostic technologies, and heightened awareness about early disease detection across emerging economies. Additionally, improvements in healthcare infrastructure and supportive government initiatives further contribute to market expansion in the Asia Pacific region.

The break-up of the profile of primary participants in the autoimmune disease diagnosis market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, the Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa- 4%

The key players in the market are Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Grifols S.A. (Spain), Werfen S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Exagen Inc. (US), Trinity Biotech plc (Ireland), Tecan Group Ltd. (Switzerland), Danaher Corporation (US), BIOSYNEX SA (France), QuidelOrtho Corporation (US), Revvity, Inc. (US), bioMerieux SA (France), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), SD Biosensor, INC. (Korea), Cambridge Life Sciences Ltd (UK), A. Menarini Diagnostics s.r.l (Italy), Sebia (France), KRONUS (US), Erba Group (Czech Republic), AESKU.GROUP GmbH (Germany), Medsource Ozone Biomedicals Pvt. Ltd. (India), and Epitope Diagnostics Inc. (US).

Research Coverage:

This research report categorizes the autoimmune disease diagnosis market by product (consumables and instruments), by test type (routine laboratory tests, inflammatory tests, autoantibodies and immunologic tests, urinalysis tests, and other tests), by disease type (systemic autoimmune diseases and organ-specific autoimmune diseases), by end user (clinical laboratories, hospitals & clinics, and other end users), and by region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the autoimmune disease diagnosis market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the autoimmune disease diagnosis market. This report covers the competitive analysis of upcoming startups in the autoimmune disease diagnosis market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall autoimmune disease diagnosis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (High incidence of autoimmune diseases, rising awareness related to early disease diagnosis, growing number of r&d activities for innovative diagnostic solutions, advancements in diagnostic technologies), restraints (high capital requirements), opportunities (utilization of biosensors for autoimmune disease diagnosis, growth potential of emerging economies, growing number of reagent rental agreements), and challenges (complexities associated with diagnosis of autoimmune diseases, shortage of skilled professionals) influencing the growth of the autoimmune disease diagnosis market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the autoimmune disease diagnosis market.
Market Development: Comprehensive information about lucrative markets - the report analyses the autoimmune disease diagnosis market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoimmune disease diagnosis market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Revvity, Inc. (US), Thermo Fisher Scientific Inc. (US), and Siemens Healthineers AG (Germany).

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Key secondary sources
  - 2.1.1.2 Key data from secondary sources
- 2.1.2 PRIMARY RESEARCH
  - 2.1.2.1 Key primary sources
  - 2.1.2.2 Key data from primary sources
  - 2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
- 2.2.1 BOTTOM-UP APPROACH
  - 2.2.1.1 Approach 1: Company revenue estimation approach
  - 2.2.1.2 Approach 2: Presentations of companies and primary interviews
  - 2.2.1.3 Growth forecast
  - 2.2.1.4 CAGR projections
- 2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
2.4 MARKET SHARE ASSESSMENT
2.5 RESEARCH ASSUMPTIONS
- 2.5.1 PARAMETRIC ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 AUTOIMMUNITY DIAGNOSTICS MARKET OVERVIEW
4.2 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2031
4.3 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2031
4.4 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2031
4.5 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2031
4.6 AUTOIMMUNITY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 High incidence of autoimmune diseases
  - 5.2.1.2 Rising awareness related to early disease diagnosis
  - 5.2.1.3 Increasing number of R&D activities for innovative diagnostic solutions
  - 5.2.1.4 Advancements in diagnostic technologies
- 5.2.2 RESTRAINTS
  - 5.2.2.1 High capital requirements
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Utilization of biosensors for autoimmune disease diagnosis
  - 5.2.3.2 Growth potential of emerging economies
  - 5.2.3.3 Growing number of reagent rental agreements
- 5.2.4 CHALLENGES
  - 5.2.4.1 Complexities associated with diagnosis of autoimmune diseases
  - 5.2.4.2 Shortage of skilled professionals
5.3 PRICING ANALYSIS
- 5.3.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT, 2023-2025
- 5.3.2 INDICATIVE SELLING PRICE TREND OF ASSAYS, BY KEY PLAYER, 2023-2025
- 5.3.3 INDICATIVE SELLING PRICE TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, BY REGION, 2023-2025
5.4 PATENT ANALYSIS
- 5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
- 5.7.1 IMPORT DATA (HS CODE 3822)
- 5.7.2 EXPORT DATA (HS CODE 3822)
5.8 ECOSYSTEM ANALYSIS
- 5.8.1 ROLE IN ECOSYSTEM
5.9 PORTER'S FIVE FORCES ANALYSIS
- 5.9.1 THREAT OF NEW ENTRANTS
- 5.9.2 THREAT OF SUBSTITUTES
- 5.9.3 BARGAINING POWER OF BUYERS
- 5.9.4 BARGAINING POWER OF SUPPLIERS
- 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.10.2 BUYING CRITERIA
- 5.10.3 REGULATORY LANDSCAPE
  - 5.10.3.1 North America
    - 5.10.3.1.1 US
    - 5.10.3.1.2 Canada
  - 5.10.3.2 Europe
    - 5.10.3.2.1 Germany
    - 5.10.3.2.2 UK
    - 5.10.3.2.3 France
    - 5.10.3.2.4 Italy
  - 5.10.3.3 Asia Pacific
    - 5.10.3.3.1 China
    - 5.10.3.3.2 Japan
    - 5.10.3.3.3 India
    - 5.10.3.3.4 Australia
  - 5.10.3.4 Latin America
  - 5.10.3.5 Middle East
    - 5.10.3.5.1 Africa
- 5.10.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 TECHNOLOGY ANALYSIS
- 5.11.1 KEY TECHNOLOGIES
  - 5.11.1.1 Immunoassays
- 5.11.2 COMPLEMENTARY TECHNOLOGIES
  - 5.11.2.1 Flow cytometry
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.14 INVESTMENT & FUNDING SCENARIO
5.15 CASE STUDY ANALYSIS
- 5.15.1 CASE STUDY 1: LABORATORY-BASED DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
- 5.15.2 CASE STUDY 2: DIAGNOSTIC IMPORTANCE OF AUTOANTIBODY TESTING IN IDENTIFICATION OF LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA)
5.16 IMPACT OF AI/GENERATIVE AI ON AUTOIMMUNITY DIAGNOSTICS MARKET
- 5.16.1 INTRODUCTION
- 5.16.2 MARKET POTENTIAL OF AI
- 5.16.3 AI USE CASES
- 5.16.4 IMPLEMENTATION OF AI, BY KEY COMPANY AND CASE
- 5.16.5 FUTURE OF AI IN AUTOIMMUNITY DIAGNOSTICS MARKET
5.17 TRUMP TARIFF IMPACT ON AUTOIMMUNITY DIAGNOSTICS MARKET
- 5.17.1 INTRODUCTION
- 5.17.2 KEY TARIFF RATES
- 5.17.3 PRICE IMPACT ANALYSIS
- 5.17.4 KEY IMPACT ON COUNTRY/REGION
  - 5.17.4.1 North America
  - 5.17.4.2 Europe
  - 5.17.4.3 Asia Pacific
- 5.17.5 IMPACT ON END-USE INDUSTRIES
  - 5.17.5.1 Clinical laboratories
  - 5.17.5.2 Hospitals & clinics

6 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT

6.1 INTRODUCTION
6.2 CONSUMABLES
- 6.2.1 RECURRING PURCHASE FOR HIGH VOLUME OF DIAGNOSTIC TESTING TO PROPEL MARKET
6.3 INSTRUMENTS
- 6.3.1 GROWING NEED FOR AUTOMATION AND HIGH-THROUGHPUT TESTING TO DRIVE MARKET

7 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE

7.1 INTRODUCTION
7.2 AUTOANTIBODIES AND IMMUNOLOGIC TESTS
- 7.2.1 ACCURATE DETECTION & MONITORING ABILITIES FOR BROAD APPLICATIONS TO PROPEL MARKET
7.3 ROUTINE LABORATORY TESTS
- 7.3.1 RECURRENT TESTING DUE TO COST EFFICIENCY TO BOOST DEMAND
7.4 INFLAMMATORY TESTS
- 7.4.1 ABILITY OF INFLAMMATORY MARKERS TO DETECT ABNORMALITIES TO DRIVE MARKET
7.5 URINALYSIS TESTS
- 7.5.1 TECHNOLOGICAL ADVANCEMENTS IN URINE ANALYZERS TO FUEL UPTAKE
7.6 OTHER TESTS

8 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE

8.1 INTRODUCTION
8.2 SYSTEMIC AUTOIMMUNE DISEASES
- 8.2.1 RHEUMATOID ARTHRITIS
  - 8.2.1.1 Uptake of rheumatoid factor immunological test to boost demand
- 8.2.2 SYSTEMIC LUPUS ERYTHEMATOSUS
  - 8.2.2.1 Utilization of autoimmune testing kits for constant monitoring to propel market
- 8.2.3 PSORIASIS
  - 8.2.3.1 Frequent association with systemic inflammation and comorbidities to boost demand
- 8.2.4 MULTIPLE SCLEROSIS
  - 8.2.4.1 Public-private investments for MS awareness to fuel market
- 8.2.5 OTHER SYSTEMIC AUTOIMMUNE DISEASES
8.3 ORGAN-SPECIFIC AUTOIMMUNE DISEASES
- 8.3.1 TYPE-1 DIABETES
  - 8.3.1.1 Rising global incidence among children & adults to fuel market
- 8.3.2 CELIAC DISEASE
  - 8.3.2.1 Growing awareness regarding gluten sensitivity and improved testing availability to drive market
- 8.3.3 INFLAMMATORY BOWEL DISEASE
  - 8.3.3.1 Growing awareness of chronic gastrointestinal autoimmune disorders to fuel market
- 8.3.4 OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASES

9 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER

9.1 INTRODUCTION
9.2 CLINICAL LABORATORIES
- 9.2.1 ABILITY TO CONDUCT HIGH VOLUME OF SPECIALIZED TESTS TO PROPEL MARKET
9.3 HOSPITALS & CLINICS
- 9.3.1 GROWING AWARENESS OF EARLY DISEASE DIAGNOSIS TO FUEL UPTAKE
9.4 OTHER END USERS

10 AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
- 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 10.2.2 US
  - 10.2.2.1 High healthcare expenditure and expansive research initiatives for product commercialization to boost demand
- 10.2.3 CANADA
  - 10.2.3.1 Rising prevalence of chronic autoimmune conditions to drive market
10.3 EUROPE
- 10.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 10.3.2 UK
  - 10.3.2.1 Growing R&D efforts for early disease diagnosis to fuel uptake
- 10.3.3 GERMANY
  - 10.3.3.1 Increasing incidence of multiple sclerosis to drive market
- 10.3.4 FRANCE
  - 10.3.4.1 Expansion of lab modernization to support market growth
- 10.3.5 ITALY
  - 10.3.5.1 Growing disease burden and aging demographics to fuel market
- 10.3.6 SPAIN
  - 10.3.6.1 Prevalence of celiac disease to drive market
- 10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
- 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 10.4.2 CHINA
  - 10.4.2.1 Government initiatives for early autoimmune disease screening to fuel market
- 10.4.3 JAPAN
  - 10.4.3.1 Rapidly aging population and advanced healthcare infrastructure to boost demand
- 10.4.4 INDIA
  - 10.4.4.1 Government-led healthcare initiatives and rapid expansion of diagnostic infrastructure to propel market
- 10.4.5 AUSTRALIA
  - 10.4.5.1 Increasing incidences of autoimmune diseases to support market growth
- 10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
- 10.5.1 INCREASING INCIDENCE OF TYPE-1 DIABETES TO FUEL MARKET
- 10.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
10.6 MIDDLE EAST & AFRICA
- 10.6.1 FAVORABLE GOVERNMENT INITIATIVES FOR EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH
- 10.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET
11.3 REVENUE ANALYSIS, 2022-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 11.5.1 STARS
- 11.5.2 EMERGING LEADERS
- 11.5.3 PERVASIVE PLAYERS
- 11.5.4 PARTICIPANTS
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 11.5.5.1 Company footprint
  - 11.5.5.2 Region footprint
  - 11.5.5.3 Product footprint
  - 11.5.5.4 Test type footprint
  - 11.5.5.5 Disease type footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 11.6.1 PROGRESSIVE COMPANIES
- 11.6.2 RESPONSIVE COMPANIES
- 11.6.3 DYNAMIC COMPANIES
- 11.6.4 STARTING BLOCKS
- 11.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  - 11.6.5.1 Detailed list of key startups/SMEs
  - 11.6.5.2 Competitive benchmarking of startups/SMEs
11.7 COMPANY VALUATION & FINANCIAL METRICS
- 11.7.1 FINANCIAL METRICS
- 11.7.2 COMPANY VALUATION
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
- 11.9.1 PRODUCT LAUNCHES & APPROVALS
- 11.9.2 DEALS
- 11.9.3 EXPANSIONS
- 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

12.1 KEY PLAYERS
- 12.1.1 F. HOFFMANN-LA ROCHE LTD.
  - 12.1.1.1 Business overview
  - 12.1.1.2 Products offered
  - 12.1.1.3 MnM view
    - 12.1.1.3.1 Key strengths
    - 12.1.1.3.2 Strategic choices
    - 12.1.1.3.3 Weaknesses & competitive threats
- 12.1.2 ABBOTT LABORATORIES
  - 12.1.2.1 Business overview
  - 12.1.2.2 Products offered
  - 12.1.2.3 MnM view
    - 12.1.2.3.1 Key strengths
    - 12.1.2.3.2 Strategic choices
    - 12.1.2.3.3 Weaknesses & competitive threats
- 12.1.3 REVVITY, INC.
  - 12.1.3.1 Business overview
  - 12.1.3.2 Products offered
  - 12.1.3.3 Recent developments
    - 12.1.3.3.1 Product launches
  - 12.1.3.4 MnM view
    - 12.1.3.4.1 Key strengths
    - 12.1.3.4.2 Strategic choices
    - 12.1.3.4.3 Weaknesses & competitive threats
- 12.1.4 THERMO FISHER SCIENTIFIC INC.
  - 12.1.4.1 Business overview
  - 12.1.4.2 Products offered
  - 12.1.4.3 Recent developments
    - 12.1.4.3.1 Product launches
    - 12.1.4.3.2 Deals
    - 12.1.4.3.3 Other developments
  - 12.1.4.4 MnM view
    - 12.1.4.4.1 Key strengths
    - 12.1.4.4.2 Strategic choices
    - 12.1.4.4.3 Weaknesses & competitive threats
- 12.1.5 SIEMENS HEALTHINEERS AG
  - 12.1.5.1 Business overview
  - 12.1.5.2 Products offered
  - 12.1.5.3 Recent developments
    - 12.1.5.3.1 Product approvals
    - 12.1.5.3.2 Deals
  - 12.1.5.4 MnM view
    - 12.1.5.4.1 Key strengths
    - 12.1.5.4.2 Strategic choices
    - 12.1.5.4.3 Weaknesses & competitive threats
- 12.1.6 BIO-RAD LABORATORIES, INC.
  - 12.1.6.1 Business overview
  - 12.1.6.2 Products offered
- 12.1.7 GRIFOLS S.A.
  - 12.1.7.1 Business overview
  - 12.1.7.2 Products offered
  - 12.1.7.3 Recent developments
    - 12.1.7.3.1 Deals
- 12.1.8 WERFEN S.A.
  - 12.1.8.1 Business overview
  - 12.1.8.2 Products offered
  - 12.1.8.3 Recent developments
    - 12.1.8.3.1 Product approvals
- 12.1.9 EXAGEN INC.
  - 12.1.9.1 Business overview
  - 12.1.9.2 Products offered
  - 12.1.9.3 Recent developments
    - 12.1.9.3.1 Product launches
    - 12.1.9.3.2 Deals
- 12.1.10 TRINITY BIOTECH PLC
  - 12.1.10.1 Business overview
  - 12.1.10.2 Products offered
- 12.1.11 TECAN GROUP LTD.
  - 12.1.11.1 Business overview
  - 12.1.11.2 Products offered
- 12.1.12 DANAHER CORPORATION
  - 12.1.12.1 Business overview
  - 12.1.12.2 Products offered
  - 12.1.12.3 Recent developments
    - 12.1.12.3.1 Deals
- 12.1.13 BIOSYNEX SA
  - 12.1.13.1 Business overview
  - 12.1.13.2 Products offered
  - 12.1.13.3 Recent developments
    - 12.1.13.3.1 Deals
- 12.1.14 QUIDELORTHO CORPORATION
  - 12.1.14.1 Business overview
  - 12.1.14.2 Products offered
  - 12.1.14.3 Recent developments
    - 12.1.14.3.1 Expansions
- 12.1.15 BIOMERIEUX SA
  - 12.1.15.1 Business overview
  - 12.1.15.2 Products offered
- 12.1.16 DIASORIN S.P.A.
  - 12.1.16.1 Business overview
  - 12.1.16.2 Products offered
  - 12.1.16.3 Recent developments
    - 12.1.16.3.1 Deals
12.2 OTHER PLAYERS
- 12.2.1 BECTON, DICKINSON AND COMPANY
- 12.2.2 SD BIOSENSOR, INC.
- 12.2.3 CAMBRIDGE LIFE SCIENCES LTD
- 12.2.4 A. MENARINI DIAGNOSTICS S.R.L
- 12.2.5 SEBIA
- 12.2.6 KRONUS
- 12.2.7 ERBA GROUP
- 12.2.8 AESKU.GROUP GMBH
- 12.2.9 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
- 12.2.10 EPITOPE DIAGNOSTICS INC.

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS